Biohaven Pharmaceutical Holding PE Ratio 2016-2021 | BHVN

Current and historical p/e ratio for Biohaven Pharmaceutical Holding (BHVN) from 2016 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Biohaven Pharmaceutical Holding PE ratio as of January 21, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Biohaven Pharmaceutical Holding PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-01-21 110.08 0.00
2021-09-30 138.91 $-13.69 0.00
2021-06-30 97.08 $-14.33 0.00
2021-03-31 68.35 $-14.18 0.00
2020-12-31 85.71 $-13.04 0.00
2020-09-30 65.01 $-12.27 0.00
2020-06-30 73.11 $-11.04 0.00
2020-03-31 34.03 $-12.63 0.00
2019-12-31 54.44 $-10.97 0.00
2019-09-30 41.72 $-9.46 0.00
2019-06-30 43.79 $-8.95 0.00
2019-03-31 51.47 $-5.29 0.00
2018-12-31 36.98 $-6.20 0.00
2018-09-30 37.55 $-5.61 0.00
2018-06-30 39.52 $-5.27 0.00
2018-03-31 25.76 $-6.04 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $7.598B $0.064B
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00